Full-Time
Updated on 9/3/2026
Purified proteins and reagents supplier
$100.8k - $165.6k/yr
No H1B Sponsorship
Minneapolis, MN, USA
In Person
Travel required approximately 25%.
Bachelor's
See people who can refer or advise you
Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Minneapolis, Minnesota
Founded
1981
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Short-term Disability
Long-term Disability
Pet Insurance
Legal Services
401(k) Company Match
Company Equity
Professional Development Budget
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
Unlimited Paid Time Off
Hybrid Work Options
Employee Stock Purchase Plan
Bio-Techne has achieved validation of its greenhouse gas reduction targets from the Science Based Targets initiative. The life sciences company aims to cut absolute Scope 1 and 2 emissions by 70% by fiscal 2031 from a fiscal 2025 baseline. In fiscal 2026, Bio-Techne reduced market-based Scope 1 and 2 emissions by 49% year-over-year. The company now sources 51% of its electricity from renewable sources after transitioning its Minneapolis headquarters and St Paul GMP facility to renewable power. Bio-Techne also committed that 81% of suppliers by spend will have science-based targets by fiscal 2030. The company completed its first comprehensive Scope 3 emissions inventory during the year. The Minnesota-based company generated over $1.2 billion in net sales in fiscal 2026.
Bio-Techne reported Q2 revenues of $321.2 million, up 1.3% year on year and exceeding analyst expectations by 2%. The life sciences company, which manufactures specialised reagents, instruments, and services for researchers, delivered a strong quarter with solid organic revenue performance. The research tools and consumables sector faces both opportunities and challenges. Whilst emerging fields like synthetic biology and personalised medicine drive demand, companies must navigate high R&D costs, pricing pressures from budget-conscious institutions, and vulnerability to research funding fluctuations. The 10 research tools and consumables stocks tracked collectively beat revenue estimates by 1.7% in Q2. Share prices have risen 6.3% on average since the latest earnings results.
Bio-Techne Corporation reported adjusted earnings per share of 52 cents for the fourth quarter of fiscal 2026, meeting the Zacks Consensus Estimate despite a 1.9% year-over-year decline. GAAP EPS was 35 cents, compared to a loss of 11 cents in the prior-year quarter. Fourth-quarter net sales reached $321.2 million, up 1% year over year on a reported basis and 3% organically, surpassing the consensus estimate by 1.26%. Full-year revenues were $1.22 billion, remaining flat from fiscal 2025. The Protein Sciences segment generated revenues of $231.2 million, up 2% year over year. Diagnostics and Spatial Biology revenues remained roughly flat at $90.1 million. Gross margin expanded 310 basis points to 65.8%. The company generated operating income of $74.3 million, compared to an operating loss of $23.9 million in the year-ago quarter. Following the announcement, shares edged up 0.1% to close at $72.23.
Bio-Techne reported mixed Q1 results with revenues of $311.4 million, down 1.5% year on year and falling short of analysts' expectations by 1.6%. The company, which manufactures specialised reagents, instruments, and services for researchers, saw its EPS meet analysts' estimates whilst organic revenue missed expectations. The research tools and consumables sector overall performed better, with the 10 tracked stocks beating revenue consensus estimates by 1.3% as a group. Next quarter's revenue guidance came in 2% above expectations. Share prices in the sector have risen 21.8% on average since the latest earnings results. The sector benefits from recurring revenue streams and customer loyalty but faces challenges including R&D investment requirements and vulnerability to research funding fluctuations.
Bio-Techne launches expanded R&D Systems AI-Engineered Designer Protein portfolio. Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems(TM) AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. A guide to advancing biotherapeutic research eBook. Welcome to your essential guide to advancing biotherapeutic research. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing. Early adopters of R&D Systems AI-Engineered Designer Proteins are already seeing measurable gains in cell expansion and overall workflow performance across demanding applications: "Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples fail during initial outgrowth due to insufficient cell expansion," said Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota. "IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies." This real-world feedback underscores the broader potential of the R&D Systems AI-Engineered Designer Protein platform. With its latest expansion to include additional cytokines and growth factors, the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows. As cell therapy advances from early research into clinical and commercial manufacturing, achieving consistency, robustness, and scalability across increasingly complex workflows is critical, Its AI-Engineered Designer Proteins are designed to overcome these challenges by delivering enhanced stability, activity, and performance-enabling more reproducible results and supporting seamless scale-up from discovery through production." Will Geist, President, Protein Science Segment, Bio-Techne The newly launched proteins include: * FGF-4 Heat Stable - Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. * FGF-7 Heat Stable - Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. * FGF-8b Heat Stable - Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. * IL-3 Heat Stable - Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. * IL-15 Hyperactive - Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success. Be the first to rate this article